Jubilant Draximage Radiopharmacies, Inc.

Jubilant Draximage Radiopharmacies, Inc., doing business as Jubilant Radiopharma, manufactures and distributes radiopharmaceuticals and nuclear medicine products to the Department of Veterans Affairs and the Department of Defense as a prime contractor. The company is a for-profit small disadvantaged business headquartered in Norcross, Georgia, and operates as a self-certified subsidiary of Jubilant Life Sciences Limited. Jubilant Radiopharma competes on a full-and-open basis across its entire prime portfolio; no awards carry set-aside designations except for two Total Small Business awards that total less than 1% of recent award value.

Jubilant Radiopharma's federal work centers on manufacturing and distributing specialized medical isotopes and radiopharmaceutical products for diagnostic imaging and therapeutic nuclear medicine procedures. The company supplies technetium-99m (in multiple formulations including Sodium Pertechnetate, Sestamibi, Medronate, and Mebrofenin), gallium-68 Dotatate (Netspot), iodine-123, iodine-131, fluorine-18 fluorodeoxyglucose, gallium-67 citrate, indium-111 pentetreotide, xenon-133, and cobalt-57 sheet sources, along with delivery and calibration services. Representative work includes a $1.49 million delivery order from the VA's Veterans Integrated Service Network 8 (VISN 8) for radiopharmaceuticals effective through September 2023; a $3.06 million indefinite delivery contract with VISN 4 for radiopharmaceutical supply to Lebanon VA Medical Center running through July 2029; and a $924,461 indefinite delivery contract with the Defense Health Agency for radiopharmaceuticals to Madigan Army Medical Center, Lewis-McChord, Washington, through January 2031. The company also holds single-award and multiple-award indefinite delivery contracts and blanket purchase agreements across nine VA regional networks, with individual vehicle ceilings ranging from $220,000 to $39.8 million.

The Department of Veterans Affairs dominates Jubilant Radiopharma's customer base. The top five customers—VISN 8, VISN 4, VISN 22, VISN 23, and VISN 10—account for 55% of recent awards by count and 73% of combined potential value. VISN 8 anchors the dollar concentration, holding a multiple-award indefinite delivery contract valued at $39.8 million (44% of the company's total combined potential value) awarded December 6, 2022, through September 30, 2027, from which numerous delivery orders have been issued for radiopharmaceutical supply to VA medical facilities across Florida and the Caribbean. The Defense Health Agency placed one award (the Madigan Army Medical Center contract noted above); all other awards flow through VA regional contracting offices.

Jubilant Radiopharma operates exclusively as a prime contractor—all 92 awards in the source represent prime work with zero subcontractor engagement. Activity has grown consistently from six awards in 2022 to 25 in 2025, with fourteen awards recorded in 2026 year to date. Ten awards with combined potential value of $2.3 million reach ultimate completion within the next twenty-four months, presenting recompete exposure primarily within VISN 10 and VISN 4. The company's contract vehicles classify predominantly under NAICS 325412 (Pharmaceutical Preparation Manufacturing), with PSC coding split between Drugs and Biologicals (76 awards) and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (10 awards). All work is performed at the company's manufacturing and distribution facility in Norcross, Georgia, or at subordinate VA locations, with Nuclear Regulatory Commission licensing, hazardous materials compliance, and rapid delivery—including emergency same-day or 45-minute response capabilities—cited as standard requirements across IDIQs and purchase orders.